Neuronetics, Inc. (STIM)

Market Cap	111.59M
Revenue (ttm)	71.35M
Net Income (ttm)	-30.19M
Shares Out	29.76M
EPS (ttm)	-1.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,017
Open	3.820
Previous Close	3.860
Day's Range	3.690 - 3.900
52-Week Range	1.030 - 5.070
Beta	2.44
Analysts	Buy
Price Target	10.00 (+166.67%)
Earnings Date	May 7, 2024

About STIM

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 28, 2018
• Employees: 203
• Stock Exchange: NASDAQ
• Ticker Symbol: STIM

Financial Performance

In 2023, Neuronetics's revenue was $71.35 million, an increase of 9.42% compared to the previous year's $65.21 million. Losses were -$30.19 million, -18.76% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for STIM stock is "Buy." The 12-month stock price forecast is $10.0, which is an increase of 166.67% from the latest price.

Price Target

$10.0

(166.67% upside)

Analyst Consensus: Buy